Thrombotic thrombocytopenic purpura-haemolytic uremic syndrome in relapsing–remitting multiple sclerosis patients on high-dose interferon beta

McGraw CA Lublin FD . Interferon beta and glatiramer acetate therapy. Neurotherapeutics 2013; 10: 2–18.

Dlott JS Danielson CF Blue-Hnidy DE . Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: A concise review. Ther Apher Dial 2004; 8: 102–111.

Hansen T New D Reeve R . Acute renal failure, systemic lupus erythematosus and thrombotic microangiopathy following treatment with beta-interferon for multiple sclerosis: Case report and review of the literature. Clin Kidney J 2009; 2: 466–468.

ema.europa.eu (homepage on the internet). European public assessment reports for Avonex®, Betaferon®, Extavia®, and Rebif® (last updated on 22 September 2011, 5 February 2013, 18 February 2013 and 6 June 2013, respectively). Available from: http://www.ema.europa.eu/ema (accessed 9 February 2014).

Tsai HM . Untying the knot of thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome. Am J Med 2013; 126: 200–209.

Aster RH Bougie DW . Drug-induced immune thrombocytopenia. N Engl J Med 2007; 357: 580–587.

Orvain C Augusto JF Besson V . Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis. Int Urol Nephrol 2014; 46: 239–242.

George JN . Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354: 1927–1935.

Olea T Díaz-Mancebo R Picazo ML . Thrombotic microangiopathy associated with use of interferon-beta. Int J Nephrol Renovasc Dis 2012; 5: 97–100.

Broughton A Cosyns JP Jadoul M . Thrombotic microangiopathy induced by long-term interferon-β therapy for multiple sclerosis: A case report. Clin Nephrol 2011; 76: 396–400.

Mahe J Meurette A Moreau A . Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis. Drug Des Devel Ther 2013; 7: 723–728.